Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01127880 · ClinicalTrials.gov registry record · Phase 2

Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax

A Phase 2 study of Pneumothorax and Hemopneumothorax, sponsored by St. Luke's Hospital, Pennsylvania.

Completed
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT01127880 is a Phase 2 study of Pneumothorax and Hemopneumothorax that has completed, run by St. Luke's Hospital, Pennsylvania. The registered enrollment target is 50 participants, below the 636-participant average among 6 other Pneumothorax trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01127880, a Phase 2 study of Pneumothorax and Hemopneumothorax, has completed, sponsored by St. Luke's Hospital, Pennsylvania.

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the efficacy of prophylactic antibiotics in patients with chest tubes for management of thoracic injuries in the reduction of the incidence of empyema as compared to placebo.

Interventions

  • DRUG Placebo
  • DRUG Ancef or Clindamycin

Study Locations (1)

Pennsylvania

  • St. Luke's Hospital and Health Network - Bethlehem

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2005-07
Est. Completion 2009-12
Phase Phase 2

Sponsor

St. Luke's Hospital, Pennsylvania

10 total trials

What the Registry Record Tells You About NCT01127880

The ClinicalTrials.gov registry entry for NCT01127880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 636-participant average among 6 other Pneumothorax trials with a reported enrollment target (92% lower). The listed sponsor is St. Luke's Hospital, Pennsylvania, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pneumothorax appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01127880 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01127880 about?

NCT01127880 is a clinical study titled "Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax". The purpose of this study is to examine the efficacy of prophylactic antibiotics in patients with chest tubes for management of thoracic injuries in the reduction of the incidence of empyema as compared to placebo.

What is the current status of trial NCT01127880?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-07. Estimated completion is 2009-12.

What conditions does trial NCT01127880 study?

This clinical trial studies the following conditions: Pneumothorax, Hemopneumothorax.

What interventions are being tested in trial NCT01127880?

The interventions under investigation include: Placebo (DRUG), Ancef or Clindamycin (DRUG).

Who is sponsoring clinical trial NCT01127880?

This trial is sponsored by St. Luke's Hospital, Pennsylvania, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01127880 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pneumothorax

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.